Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome.

Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G.

Can J Psychiatry. 2004 Nov;49(11):753-60.

PMID:
15633853
2.

Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs.

Correll CU, Frederickson AM, Kane JM, Manu P.

J Clin Psychiatry. 2006 Apr;67(4):575-83.

PMID:
16669722
3.

Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders.

Onat A, Hergenç G, Sansoy V, Fobker M, Ceyhan K, Toprak S, Assmann G.

Atherosclerosis. 2003 May;168(1):81-9.

PMID:
12732390
4.

A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls.

Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S, D'Agostino RB, Stroup TS, Davis S, Lieberman JA.

Schizophr Res. 2005 Dec 1;80(1):45-53. Epub 2005 Sep 28.

PMID:
16198088
5.

A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study.

Arango C, Bobes J, Aranda P, Carmena R, Garcia-Garcia M, Rejas J; CLAMORS Study Collaborative Group.

Schizophr Res. 2008 Sep;104(1-3):1-12. doi: 10.1016/j.schres.2008.05.009. Epub 2008 Jul 7.

PMID:
18606526
6.

Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study.

Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J; CLAMORS Study Collaborative Group.

Schizophr Res. 2007 Feb;90(1-3):162-73. Epub 2006 Nov 21.

PMID:
17123783
7.

Metabolic syndrome and cardiovascular risk among patients with schizophrenia receiving antipsychotics in Malaysia.

Said MA, Sulaiman AH, Habil MH, Das S, Bakar AK, Yusoff RM, Loo TH, Bakar SA.

Singapore Med J. 2012 Dec;53(12):801-7.

8.
9.

Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms.

Jin H, Folsom D, Sasaki A, Mudaliar S, Henry R, Torres M, Golshan S, Glorioso DK, Jeste D.

Schizophr Res. 2011 Feb;125(2-3):295-9. doi: 10.1016/j.schres.2010.10.029. Epub 2010 Nov 19.

10.

NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older.

Alexander CM, Landsman PB, Teutsch SM, Haffner SM; Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP).

Diabetes. 2003 May;52(5):1210-4.

11.

Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan.

Huang TL, Chen JF.

Schizophr Res. 2005 Dec 1;80(1):55-9. Epub 2005 Jun 17.

PMID:
15964176
13.

Cardiovascular and metabolic risk in outpatients with schizoaffective disorder treated with antipsychotics: results from the CLAMORS study.

Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J; CLAMORS Study Collaborative Group.

Eur Psychiatry. 2012 May;27(4):267-74. doi: 10.1016/j.eurpsy.2010.09.001. Epub 2010 Oct 30.

PMID:
21036549
14.
15.

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly.

Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9. French.

PMID:
19748369
16.

The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey.

Yazici MK, Anil Yağcioğlu AE, Ertuğrul A, Eni N, Karahan S, Karaağaoğlu E, Tokgözoğlu SL.

Eur Arch Psychiatry Clin Neurosci. 2011 Feb;261(1):69-78. doi: 10.1007/s00406-010-0118-x. Epub 2010 Jun 3.

PMID:
20517698
17.

Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: findings from the CLAMORS study.

Arango C, Bobes J, Kirkpatrick B, Garcia-Garcia M, Rejas J.

Eur Neuropsychopharmacol. 2011 Dec;21(12):867-75. doi: 10.1016/j.euroneuro.2011.03.005. Epub 2011 Apr 7.

PMID:
21477998
18.

Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels--a prospective and cross-sectional evaluation.

Onat A, Ceyhan K, Başar O, Erer B, Toprak S, Sansoy V.

Atherosclerosis. 2002 Dec;165(2):285-92.

PMID:
12417279
19.

Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness.

Ratliff JC, Palmese LB, Reutenauer EL, Srihari VH, Tek C.

Psychosomatics. 2013 Jan-Feb;54(1):67-73. doi: 10.1016/j.psym.2012.03.001. Epub 2012 Jun 2.

20.

[Metabolic side effects of risperidone in early onset schizophrenia].

Goeb JL, Marco S, Duhamel A, Kechid G, Bordet R, Thomas P, Delion P, Jardri R.

Encephale. 2010 Jun;36(3):242-52. doi: 10.1016/j.encep.2009.10.008. Epub 2009 Dec 1. French.

PMID:
20620267

Supplemental Content

Support Center